KUKohei Unagami

Kohei Unagami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kohei Unagami has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety and Efficacy of Selective Plasma Exchange Versus Conventional Plasma Exchange in Pretransplant Desensitization of ABO ‐Incompatible Kidney Transplantation

    by Takahiro Inoue, Hajime Hirano, Yu Munakata, Yuki Kawaguchi, Ken Tsuchiya, Kohei Unagami, Junichi Hoshino, Hideki Ishida, Toshio Takagi, Norio Hanafusa

    Selective plasma exchange (SePE) may reduce adverse events associated with fresh frozen plasma (FFP) use during pretransplant desensitization for ABO‐incompatible kidney transplantation. We conducted a single‐center retrospective cohort study of 75 patients who underwent ABO‐incompatible kidney transplantation between January 2020 and April 2024. Of these, 48 received SePE and 27 received conventional plasma exchange (CPE) with FFP. We compared antibody titers at transplantation, perioperative outcomes, and procedure‐related adverse events between the groups. Adverse events occurred in 5 patients (10.4%) in the SePE group and 17 patients (63.0%) in the CPE group ( p < 0.001). Anaphylactic shock occurred in no patients in the SePE group and 4 patients (14.8%) in the CPE group ( p = 0.027). All patients in the SePE group and all but one patient in the CPE group achieved the prespecified preoperative antibody titer target of ≤ 1:32. Neither surgical operating time nor intraoperative blood loss differed significantly between the groups. In this cohort, SePE was associated with fewer procedure‐related adverse events than CPE with FFP while achieving the preoperative antibody titer target in all SePE‐treated patients.

  • Open Access

    Early Post-Transplant Hyperuricemia and Association with Histologic Fibrosis Progression and EMT-Related Changes in Proximal Tubular Cells

    by Mayuko Kawabe, Yasuyuki Nakada, Izumi Yamamoto, Akimitsu Kobayashi, Kohei Unagami, Toshihito Hirai, Kazuya Omoto, Tomokazu Shimizu, Takashi Yokoo, Toshio Takagi, et al.

    Background: Hyperuricemia is common after kidney transplantation and frequently arises with calcineurin inhibitor exposure and reduced graft function. However, its role in development of interstitial fibrosis and tubular atrophy (IF/TA) remains unclear. This study examined the association between post-transplant hyperuricemia and histologic fibrosis progression using clinical and in vitro analyses. Methods: We retrospectively analyzed 138 non-diabetic kidney transplant recipients in the Japan Academic Consortium of Kidney Transplantation (JACK) who underwent baseline and follow-up allograft biopsies (mean interval, 4.2 ± 2.2 years). Hyperuricemia was defined as serum uric acid >7 mg/dL in men and >6 mg/dL in women at 6 months post-transplant. The primary outcome was fibrosis progression, defined as an increase of ≥2 Banff ci grades. In parallel, human proximal tubular epithelial (HK-2) cells were exposed to uric acid, and URAT1, α-smooth muscle actin (α-SMA), and E-cadherin expression was assessed. Results: Hyperuricemia at 6 months was significantly associated with IF/TA progression (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.16–3.77; p = 0.01) and remained significant after adjustment for serum creatinine and early T cell–mediated rejection (adjusted HR, 1.99; 95% CI, 1.05–3.77; p = 0.04). No association was observed with arteriolar hyalinosis progression. In HK-2 cells, uric acid induced dose-dependent α-SMA upregulation and E-cadherin downregulation, consistent with epithelial–mesenchymal transition(EMT). Conclusions: Hyperuricemia within the first 6 months after kidney transplantation was independently associated with interstitial fibrosis progression. Experimental data demonstrated EMT-related changes in tubular epithelial cells exposed to uric acid, suggesting a biological link between hyperuricemia and chronic allograft remodeling.

  • Open Access

    Safety management of kidney transplantation in patients with Behçet’s disease: A case report with literature review

    by Yuki Nemoto, Kohei Unagami, Hiroki Shirakawa, Ayaka Saitoh, Daigo Okada, Takafumi Yagisawa, Miyuki Furusawa, Toshihito Hirai, Kazuya Omoto, Tomokazu Shimizu, et al.

    Background: Behçet’s disease (BD) is a multisystem inflammatory disease of unknown etiology characterized by recurrent acute flares. Vascular lesions can present major challenges for transplantation. Solid organ transplantation in patients with BD requires careful assessment of peripheral vascular lesions. Case presentation: A 67-year-old man with BD underwent ABO-incompatible, donor-specific antibody-negative, living-donor preemptive kidney transplantation (KTx). Because of bilateral external iliac vein thrombosis, the patient received intensified anticoagulation with warfarin for 6 months, and an inferior vena cava filter was placed prior to KTx. Postoperatively, he experienced complications, including two aneurysm formations requiring stent placement; all were managed successfully, and his allograft kidney function remained stable. Conclusions: KTx in patients with BD can be performed safely when BD activity is appropriately assessed and when adequate treatment is administered preoperatively and maintained throughout the post-KTx period.

  • Open Access

    Potential of Kidney Exchange Programs (KEPs) in Japan for Donor-Specific Antibody-Positive Kidney Transplants: A Questionnaire Survey on KEPs and a Multi-Institutional Study Conducting Virtual Cross-Matching Simulations

    by Taihei Ito, Miki Ito, Naohiro Aida, Kei Kurihara, Akihiro Terao, Yoshihiko Watarai, Mitsuru Saito, Keizo Kaku, Daisuke Ishii, Satoshi Sekiguchi, et al.

    Objectives: To clarify the need for a kidney exchange program (KEP) in Japan by conducting a questionnaire survey on KEPs and simulated KEPs by virtual cross-matching based on past cases of transplantation avoidance. Methods: In addition to the content regarding KEPs, an electronic survey was conducted to investigate the number of cases of kidney transplant abandonment due to “immunological” reasons over the past 10 years (2012–2021). Virtual cross-matching was conducted to simulate the feasibility of avoiding immunological risks and enabling kidney transplantation in patients who were previously unable to undergo the procedure. Results: The survey received responses from 107 facilities (response rate: 81.7%). In response to the question about the necessity of a KEP in Japan, 71 facilities (66.4%) indicated that KEPs are necessary. In addition, 251 living-donor kidney transplants were abandoned for “immunological” reasons over the past decade (2012–2021). Among the 80 pairs for which detailed information was available, virtual cross-matching simulations showed that 37/80 pairs (46.3%) were donor-specific antibody (DSA)-negative for blood type-matched combinations, and 41/80 pairs (51.3%) were DSA-negative for blood type-incompatible transplants. Conclusions: The need for a KEP in Japan and its potential usefulness were demonstrated.


  • Open Access

    Personalized prediction model generated with machine learning for kidney function one year after living kidney donation

    by Rikako Oki, Toshihio Hirai, Kazuhiro Iwadoh, Yu Kijima, Hiroyuki Hashimoto, Yasunori Nishimura, Taro Banno, Kohei Unagami, Kazuya Omoto, Tomokazu Shimizu, et al.

    Living kidney donors typically experience approximately a 30% reduction in kidney function after donation, although the degree of reduction varies among individuals. This study aimed to develop a machine learning (ML) model to predict serum creatinine (Cre) levels at one year post-donation using preoperative clinical data, including kidney-, fat-, and muscle-volumetry values from computed tomography. A total of 204 living kidney donors were included. Symbolic regression via genetic programming was employed to create an ML-based Cre prediction model using preoperative clinical variables. Validation was conducted using a 7:3 training-to-test data split. The ML model demonstrated a median absolute error of 0.079 mg/dL for predicting Cre. In the validation cohort, it outperformed conventional methods (which assume post-donation eGFR to be 70% of the preoperative value) with higher R2 (0.58 vs. 0.27), lower root mean squared error (5.27 vs. 6.89), and lower mean absolute error (3.92 vs. 5.8). Key predictive variables included preoperative Cre and remnant kidney volume. The model was deployed as a web application for clinical use. The ML model offers accurate predictions of post-donation kidney function and may assist in monitoring donor outcomes, enhancing personalized care after kidney donation.


  • Donor‐Derived Cell‐Free DNA for Diagnosing Subclinical Rejection: A Pilot Multicenter Study in Japanese Living‐Donor Kidney Transplantation

    by Toshihito Hirai, Taro Banno, Kazuya Omoto, Tomokazu Shimizu, Sumi Hidaka, Yu Kijima, Miyuki Furusawa, Ayaka Saitoh, Kohei Unagami, Masashi Inui, et al.

    Background: Donor‐derived cell‐free DNA (dd‐cfDNA) offers a non‐invasive biomarker for detecting allograft injury. However, its performance in predominantly living‐donor transplant settings in Asian populations remains underexplored.Methods: In a multicenter prospective pilot study, 73 living‐donor kidney transplant (LKT) recipients from Japan underwent plasma dd‐cfDNA testing and protocol biopsies approximately 1 year post‐transplant. Diagnostic performance of dd‐cfDNA for subclinical antibody‐mediated rejection (AMR) was evaluated at 1.0% and 0.5% cut‐off thresholds.Results: Eight patients (11.0%) were diagnosed with subclinical active AMR. Patients with dd‐cfDNA ≥1.0% showed significantly higher incidence of AMR compared to those with dd‐cfDNA p < 0.001). ROC analysis revealed an AUC of 0.85 for dd‐cfDNA in diagnosing AMR. Lowering the threshold to 0.5% improved sensitivity while maintaining high specificity. Patients with persistent donor‐specific antibodies (DSA) at 1‐year follow‐up exhibited significantly higher dd‐cfDNA levels. Neither HLA nor ABO incompatibility nor donor‐recipient relation significantly affected dd‐cfDNA levels.Conclusion: dd‐cfDNA demonstrates high negative predictive value and complements DSA testing for early detection of subclinical AMR in living‐donor transplants. This pilot study provides foundational evidence for dd‐cfDNA‐based surveillance strategies in Asian cohorts.


  • Open Access

    Perioperative management of kidney transplantation in patients with myasthenia gravis: a case report with literature review

    by Ayaka Saitoh, Kohei Unagami, Takahiro Inoue, Yu Kijima, Daigo Okada, Miyuki Furusawa, Kumiko Kitajima, Toshihito Hirai, Kazuya Omoto, Tomokazu Shimizu, et al.

    Background: Myasthenia gravis (MG) is an autoimmune disease with the disorder of the neuromuscular junction, characterized by muscle weakness and easy fatigue. The disease is associated with the development of a myasthenic crisis caused by invasiveness or other factors. MG treatment includes immunosuppressants and blood purification therapy, similar to the immunosuppressive management in kidney transplantation (KTx). We performed KTx in patients with MG. Case presentation: A female patient with chronic renal failure had already been diagnosed with MG, and she had been treated with tacrolimus (TAC) and methylprednisolone (MP). Immunoadsorption therapy was performed twice weekly along with hemodialysis therapy. At 57 years of age, the patient underwent ABO-compatible, donor-specific antibody-positive living donor KTx. TAC, mycophenolate mofetil, MP, basiliximab, and rituximab were administered as immunosuppressants. Plasmapheresis and intravenous immunoglobulins were administered prior to KTx. Conclusions: In addition to perioperative invasiveness, a postoperative urinary tract infection had occurred, raising concerns regarding the onset of a crisis. However, the impact of plasmapheresis and other immunosuppressive therapies may have had a positive influence on the perioperative management in this case.

  • Outcomes of kidney transplantation in recipients with SARS-cov-2 infection: a 282-case single-center experience in Japan

    by Eri Sekido, Kohei Unagami, Kazuya Omoto, Ken Arimura, Ikumi Moriyama, Taro Banno, Ayaka Saitoh, Rikako Oki, Daigo Okada, Takafumi Yagisawa, et al.

    Background The coronavirus disease 2019, caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has become a global epidemic. There are concerns regarding the severity of SARS-CoV-2 infections in kidney transplant (KTx) recipients. However, there is limited data on how the epidemic has affected the treatment and prognosis of these patients. Therefore, we aimed to report the changes in the treatment and outcomes of KTx recipients infected with SARS-CoV-2 during each wave at our institution. Methods A total of 282 KTx recipients who were infected with SARS-CoV-2 during the study period were followed up at Tokyo Women’s Medical University between March 2020 and August 2022. We investigated the outcomes and treatments of infected KTx recipients. Results Nineteen (6.7%) patients showed severe outcomes, including eight SARS-CoV-2 infection-related deaths. Risk factors associated with severe outcomes included underlying conditions, such as diabetes mellitus, heart disease, and liver disease (odds ratios, 2.09, 2.88, and 5.52, respectively). Treatment strategies changed throughout the epidemic in response to changes in the SARS-CoV-2 variants. Antiviral drugs were gradually administered as soon as they were approved for use. Conclusions Treatment strategies for KTx recipients were gradually established over the course of the epidemic. Although the proportion of infected KTx recipients decreased compared to that of the general population throughout the epidemic, many patients still followed a severe course.

  • Renal outcome of living kidney donors aged more than 70 years

    by Rikako Oki, Kohei Unagami, Taro Banno, Toshihito Hirai, Kazuya Omoto, Tomokazu Shimizu, Sekiko Taneda, Junichi Hoshino, Toshio Takagi, Hideki Ishida

    Background The number of marginal living kidney donors has increased. Medically complex donors who have hypertension, older age, or low estimated glomerular filtration rate (eGFR) have been more likely to be used. Methods We conducted a retrospective cohort study of living kidney donors at a single center. We analyzed 309 living donors and divided them into three groups: group with older donors (aged ≥70 years) (n = 41), middle-aged (aged 46–69 years) (n = 239), and young donors (aged N = 29). Donor factors associated with chronic kidney disease (CKD) stage 3b or worse within 5 years post-donation were investigated. Results Of the 309 live donors, 86 (27.8%) developed CKD stage3b or worse within 5 years post-donation. The incidence of CKD stage3b or worse within 5 years post-donation was significantly higher in older donor (p < 0.01). Cox regression models revealed that older donor ages and lower eGFR were significantly related to the development of CKD stage3b or worse, independent of comorbidities such as obesity and hypertension [hazard ratio (95% CI); 4.59 (1.02–20.6), p = 047, 0.95 (0.94–0.96), p ≤ 0.01, respectively]. However, recovery of eGFR 4–5 years after donation was noted in the middle-aged and older donor groups, whereas the level of eGFR remained unchanged in the young group. Conclusions Older donors tend to develop CKD stage3b within 5 years post-donation but with the potential of recovery. Healthy older people (aged ≥70 years) could be candidates for living donors under careful monitoring of kidney function after donation.


  • The medical cost and outcome of desensitization protocol in kidney transplantation recipients with high immunological risks

    by Ryoichi Maenosono, Kohei Unagami, Rikako Oki, Yuya Fujiwara, Taro Banno, Daigo Okada, Takafumi Yagisawa, Taichi Kanzawa, Toshihito Hirai, Kazuya Omoto, et al.

    Background: Kidney transplantation is a well‐established alternative in renal replacement therapy. Compared with hemodialysis, low‐immunological‐risk kidney transplantation can reduce the medical treatment costs associated with end‐stage renal disease. However, there are few reports on whether high‐immunological‐risk kidney transplantation reduces the financial burden on governments. We investigated the medical costs of high‐immunological‐risk kidney transplantation in comparison with the cost of hemodialysis in Japan.Methods: We compared the medical costs of high‐immunological‐risk kidney transplantation with those of hemodialysis. 15 patients who underwent crossmatch‐positive and/or donor‐specific antibody‐positive kidney transplantations between 2020 and 2021 were enrolled in this study. The patients received intravenous immunoglobulin, plasmapheresis, and rituximab as desensitizing therapy.Results: Acute antibody‐mediated rejection was detected in nine (60%) recipients, while there were no indications of graft function deterioration during the follow‐up. For each patient, the transplant hospitalization cost was 38 428 ± 8789 USD. However, the cumulative costs were 59 758 ± 10 006 USD and 79 781 ± 16 366 USD, at 12 and 24 months, respectively. Compared with hemodialysis (34 286 USD per year), high‐immunological‐risk kidney transplantation tends to be expensive in the first year, but the cost is likely to be lower than that of hemodialysis after 3 years.Conclusions: Although kidney transplantation is initially expensive compared with hemodialysis, the medical cost becomes advantageous after 3 years even in kidney transplant recipients with high immunological risk.